Skip to Content

Merck KGaA MKGAF

Morningstar Rating
$173.00 +3.00 (1.76%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MKGAF is trading within a range we consider fairly valued.
Price
$172.14
Fair Value
$427.97
Uncertainty
High
1-Star Price
$511.66
5-Star Price
$848.35
Economic Moat
Jwlckn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MKGAF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$170.00
Day Range
$171.26173.00
52-Week Range
$143.46196.23
Bid/Ask
$168.06 / $174.43
Market Cap
$75.22 Bil
Volume/Avg
350 / 2,077

Key Statistics

Price/Earnings (Normalized)
18.92
Price/Sales
3.29
Dividend Yield (Trailing)
1.41%
Dividend Yield (Forward)
1.38%
Total Yield
1.41%

Company Profile

Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Core
Total Number of Employees
63,297

Competitors

Valuation

Metric
MKGAF
BIIB
DHR
Price/Earnings (Normalized)
18.9215.0030.03
Price/Book Value
2.522.163.54
Price/Sales
3.293.277.96
Price/Cash Flow
15.0114.6527.62
Price/Earnings
MKGAF
BIIB
DHR

Financial Strength

Metric
MKGAF
BIIB
DHR
Quick Ratio
0.860.921.18
Current Ratio
1.562.001.68
Interest Coverage
12.895.1317.58
Quick Ratio
MKGAF
BIIB
DHR

Profitability

Metric
MKGAF
BIIB
DHR
Return on Assets (Normalized)
6.04%8.29%5.68%
Return on Equity (Normalized)
11.03%15.11%9.47%
Return on Invested Capital (Normalized)
8.21%10.01%6.69%
Return on Assets
MKGAF
BIIB
DHR
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AWskw$87.4 Bil
MKKGY
Merck KGaA ADRJhqqhv$74.3 Bil
HLN
Haleon PLC ADRCtv$38.5 Bil
VTRS
Viatris IncDgq$15.1 Bil
RDY
Dr Reddy's Laboratories Ltd ADRVgynw$12.4 Bil
CTLT
Catalent IncFytyzt$10.3 Bil
CURLF
Curaleaf Holdings IncYkgz$3.6 Bil
PRGO
Perrigo Co PLCWywgk$3.6 Bil
PBH
Prestige Consumer Healthcare IncQmzqpcd$3.5 Bil
GTBIF
Green Thumb Industries IncKgc$3.1 Bil

Sponsor Center